Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

Association between ERCC1 C8092A and ERCC2 K751Q polymorphisms and risk of adult glioma: a meta-analysis

verfasst von: Zhiqin Xu, Wenbin Ma, Lu Gao, Bing Xing

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

While the ERCC1 C8092A and ERCC2 K751Q polymorphisms have received much attention for their potential associations with adult glioma risk, inferences from such studies are hindered by their limited statistical power and conflicting results. The aim of this meta-analysis is to provide a relatively comprehensive account of the association between these two polymorphisms and adult glioma risk. A literature search for eligible studies published before September 1, 2013 was conducted in PubMed, Embase, Web of Science, Cochrane Library, and CNKI databases. Pooled odds ratios (ORs) with their corresponding 95 % confidence intervals (95 % CIs) were used to evaluate the strength of the association under a fixed or random effect model according to heterogeneity test results. All analyses were performed using STATA software, version 12.0. Ten case–control studies were included in this meta-analysis, with a total of 5,843 adult glioma patients and 8,139 healthy controls. For ERCC1 C8092A (dbSNP: rs3212986, C>A), the combined results show that carriers of the AA genotype may be associated with a higher risk of adult glioma than carriers of the CA and CC genotypes. Stratified analyses show that the magnitude of the effect was especially significant among Asians, indicating ethnicity differences in adult glioma susceptibility. For ERCC2 K751Q (dbSNP: rs13181, A>C), the pooled ORs were not significant in the overall population, although all of the ORs were greater than 1. However, Asians seem to be significantly more susceptible to adult glioma than Caucasians. The results of this meta-analysis indicate that the AA genotype of ERCC1 C8092A may be associated with a higher risk of adult glioma than the CA and CC genotypes and that the risk allele of ERCC2 K751Q confers a significant susceptibility to adult glioma, especially in Asian populations. These polymorphisms may be used along with other genetic markers to identify individuals at high risk for adult glioma.
Literatur
1.
Zurück zum Zitat Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2:494–503. quiz 1 p following 16.PubMedCrossRef Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2:494–503. quiz 1 p following 16.PubMedCrossRef
2.
Zurück zum Zitat Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the united states in 2005–2009. Neuro Oncol. 2012;14 Suppl 5:v1–v49.PubMedCentralPubMedCrossRef Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the united states in 2005–2009. Neuro Oncol. 2012;14 Suppl 5:v1–v49.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol. 2004;36:1046–69.PubMedCrossRef Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol. 2004;36:1046–69.PubMedCrossRef
4.
Zurück zum Zitat Plascak JJ, Fisher JL. Area-based socioeconomic position and adult glioma: a hierarchical analysis of surveillance epidemiology and end results data. PLoS One. 2013;8:e60910.PubMedCentralPubMedCrossRef Plascak JJ, Fisher JL. Area-based socioeconomic position and adult glioma: a hierarchical analysis of surveillance epidemiology and end results data. PLoS One. 2013;8:e60910.PubMedCentralPubMedCrossRef
5.
6.
Zurück zum Zitat Burcham PC. Internal hazards: baseline DNA damage by endogenous products of normal metabolism. Mutat Res. 1999;443:11–36.PubMedCrossRef Burcham PC. Internal hazards: baseline DNA damage by endogenous products of normal metabolism. Mutat Res. 1999;443:11–36.PubMedCrossRef
7.
Zurück zum Zitat Liu BH, Yu FY, Wu TS, Li SY, Su MC, et al. Evaluation of genotoxic risk and oxidative DNA damage in mammalian cells exposed to mycotoxins, patulin and citrinin. Toxicol Appl Pharmacol. 2003;191:255–63.PubMedCrossRef Liu BH, Yu FY, Wu TS, Li SY, Su MC, et al. Evaluation of genotoxic risk and oxidative DNA damage in mammalian cells exposed to mycotoxins, patulin and citrinin. Toxicol Appl Pharmacol. 2003;191:255–63.PubMedCrossRef
9.
Zurück zum Zitat Ames BN. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat Res. 2001;475:7–20.PubMedCrossRef Ames BN. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer. Mutat Res. 2001;475:7–20.PubMedCrossRef
10.
Zurück zum Zitat Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:193–204.PubMedCrossRef Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:193–204.PubMedCrossRef
11.
Zurück zum Zitat Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.PubMed Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.PubMed
12.
13.
Zurück zum Zitat Smith JS, Tachibana I, Pohl U, Lee HK, Thanarajasingam U, et al. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics. 2000;64:44–50.PubMedCrossRef Smith JS, Tachibana I, Pohl U, Lee HK, Thanarajasingam U, et al. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics. 2000;64:44–50.PubMedCrossRef
14.
Zurück zum Zitat Garcia-Closas M, Malats N, Real FX, Welch R, Kogevinas M, et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:536–42.PubMedCrossRef Garcia-Closas M, Malats N, Real FX, Welch R, Kogevinas M, et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:536–42.PubMedCrossRef
15.
Zurück zum Zitat Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends Genet. 2004;20:439–44.PubMedCrossRef Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends Genet. 2004;20:439–44.PubMedCrossRef
16.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.PubMedCentralPubMedCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, et al. Strengthening the Reporting of Genetic Association studies (STREGA): an extension of the STROBE statement. Hum Genet. 2009;125:131–51.PubMedCrossRef Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, et al. Strengthening the Reporting of Genetic Association studies (STREGA): an extension of the STROBE statement. Hum Genet. 2009;125:131–51.PubMedCrossRef
18.
Zurück zum Zitat Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.PubMedCrossRef Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.PubMedCrossRef
19.
20.
Zurück zum Zitat Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef
21.
Zurück zum Zitat Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–80.PubMedCrossRef Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–80.PubMedCrossRef
23.
Zurück zum Zitat Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, et al. Association of an ercc1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev. 2000;9:843–7.PubMed Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, et al. Association of an ercc1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev. 2000;9:843–7.PubMed
24.
25.
Zurück zum Zitat Liu Y, Scheurer ME, El-Zein R, Cao Y, Do KA, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009;18:204–14.PubMedCentralPubMedCrossRef Liu Y, Scheurer ME, El-Zein R, Cao Y, Do KA, et al. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009;18:204–14.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, Ruder AM, Butler M, et al. Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev. 2009;18:1118–26.PubMedCentralPubMedCrossRef McKean-Cowdin R, Barnholtz-Sloan J, Inskip PD, Ruder AM, Butler M, et al. Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev. 2009;18:1118–26.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Chen DQ, Yao DX, Zhao HY, Yang SJ. DNA repair gene ERCC1 and XPD polymorphisms predict glioma susceptibility and prognosis. Asian Pac J Cancer Prev. 2012;13:2791–4.PubMedCrossRef Chen DQ, Yao DX, Zhao HY, Yang SJ. DNA repair gene ERCC1 and XPD polymorphisms predict glioma susceptibility and prognosis. Asian Pac J Cancer Prev. 2012;13:2791–4.PubMedCrossRef
28.
Zurück zum Zitat Zhang N, Lin LY, Zhu LL, Wu F, Wen H, et al. ERCC1 polymorphisms and risk of adult glioma in a Chinese population: a hospital-based case–control study. Cancer Invest. 2012;30:199–202.PubMedCrossRef Zhang N, Lin LY, Zhu LL, Wu F, Wen H, et al. ERCC1 polymorphisms and risk of adult glioma in a Chinese population: a hospital-based case–control study. Cancer Invest. 2012;30:199–202.PubMedCrossRef
29.
30.
Zurück zum Zitat Caggana M, Kilgallen J, Conroy JM, Wiencke JK, Kelsey KT, et al. Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev. 2001;10:355–60.PubMed Caggana M, Kilgallen J, Conroy JM, Wiencke JK, Kelsey KT, et al. Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev. 2001;10:355–60.PubMed
31.
Zurück zum Zitat Rajaraman P, Hutchinson A, Wichner S, Black PM, Fine HA, et al. DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol. 2010;12:37–48.PubMedCentralPubMedCrossRef Rajaraman P, Hutchinson A, Wichner S, Black PM, Fine HA, et al. DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol. 2010;12:37–48.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Luo KQ, Mu SQ, Wu ZX, Shi YN, Peng JC. Polymorphisms in DNA repair genes and risk of glioma and meningioma. Asian Pac J Cancer Prev. 2013;14:449–52.PubMedCrossRef Luo KQ, Mu SQ, Wu ZX, Shi YN, Peng JC. Polymorphisms in DNA repair genes and risk of glioma and meningioma. Asian Pac J Cancer Prev. 2013;14:449–52.PubMedCrossRef
33.
Zurück zum Zitat Vanan I, Dong Z, Tosti E, Warshaw G, Symons M, et al. Role of a DNA damage checkpoint pathway in ionizing radiation-induced glioblastoma cell migration and invasion. Cell Mol Neurobiol. 2012;32:1199–208.PubMedCrossRef Vanan I, Dong Z, Tosti E, Warshaw G, Symons M, et al. Role of a DNA damage checkpoint pathway in ionizing radiation-induced glioblastoma cell migration and invasion. Cell Mol Neurobiol. 2012;32:1199–208.PubMedCrossRef
34.
Zurück zum Zitat Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J. 2009;417:639–50.PubMedCentralPubMedCrossRef Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J. 2009;417:639–50.PubMedCentralPubMedCrossRef
36.
Zurück zum Zitat Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41:899–904.PubMedCrossRef Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009;41:899–904.PubMedCrossRef
37.
Zurück zum Zitat Rajaraman P, Melin BS, Wang Z, McKean-Cowdin R, Michaud DS, et al. Genome-wide association study of glioma and meta-analysis. Hum Genet. 2012;131:1877–88.PubMedCentralPubMedCrossRef Rajaraman P, Melin BS, Wang Z, McKean-Cowdin R, Michaud DS, et al. Genome-wide association study of glioma and meta-analysis. Hum Genet. 2012;131:1877–88.PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Lai R, Crevier L, Thabane L. Genetic polymorphisms of glutathione S-transferases and the risk of adult brain tumors: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2005;14:1784–90.PubMedCrossRef Lai R, Crevier L, Thabane L. Genetic polymorphisms of glutathione S-transferases and the risk of adult brain tumors: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2005;14:1784–90.PubMedCrossRef
39.
Zurück zum Zitat Tan D, Xu J, Li Y, Lai R. Association between +61g polymorphism of the EGF gene and glioma risk in different ethnicities: a meta-analysis. Tohoku J Exp Med. 2010;222:229–35.PubMedCrossRef Tan D, Xu J, Li Y, Lai R. Association between +61g polymorphism of the EGF gene and glioma risk in different ethnicities: a meta-analysis. Tohoku J Exp Med. 2010;222:229–35.PubMedCrossRef
40.
Zurück zum Zitat Jacobs DI, Bracken MB. Association between XRCC1 polymorphism 399 g→a and glioma among Caucasians: a systematic review and meta-analysis. BMC Med Genet. 2012;13:97.PubMedCentralPubMedCrossRef Jacobs DI, Bracken MB. Association between XRCC1 polymorphism 399 g→a and glioma among Caucasians: a systematic review and meta-analysis. BMC Med Genet. 2012;13:97.PubMedCentralPubMedCrossRef
41.
Zurück zum Zitat He F, Xia Y, Liu H, Li J, Wang C. P53 codon 72 arg/pro polymorphism and glioma risk: an updated meta-analysis. Tumour Biol. 2013;34:3121–30.PubMedCrossRef He F, Xia Y, Liu H, Li J, Wang C. P53 codon 72 arg/pro polymorphism and glioma risk: an updated meta-analysis. Tumour Biol. 2013;34:3121–30.PubMedCrossRef
42.
Zurück zum Zitat Lu Q, Dai D, Zhao W, Wang L, Yue Z, et al. Association between mthfr 677c>t polymorphism and risk of gliomas: evidence from a meta-analysis. Tumour Biol. 2013;34:2801–7.PubMedCrossRef Lu Q, Dai D, Zhao W, Wang L, Yue Z, et al. Association between mthfr 677c>t polymorphism and risk of gliomas: evidence from a meta-analysis. Tumour Biol. 2013;34:2801–7.PubMedCrossRef
Metadaten
Titel
Association between ERCC1 C8092A and ERCC2 K751Q polymorphisms and risk of adult glioma: a meta-analysis
verfasst von
Zhiqin Xu
Wenbin Ma
Lu Gao
Bing Xing
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1420-9

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.